Stockscreener 앱 받기
2.60
0.78%
0.02
Aytu Biopharma Inc 주식(AYTU)의 최신 뉴스
Gainers Report: Will Aytu BioPharma Inc stock benefit from M A2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 - ACCESS Newswire
Pharma News: Will Aytu BioPharma Inc benefit from rising consumer demandQuarterly Market Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Aytu launches EXXUA, first selective 5-HT1A agonist for depression By Investing.com - Investing.com South Africa
Aytu BioPharma Highlights EXXUA Opportunity at Investor Day - TipRanks
Aytu BioPharma Recaps Investor Day Held on January 20, 2026 - ACCESS Newswire
Aytu BioPharma Recaps Investor Day and EXXUA Launch - TradingView
New EXXUA depression drug targets MDD without sexual side effects - Stock Titan
AYTU: Exxua launches as a differentiated MDD therapy, targeting growth with disciplined, scalable execution - TradingView
AYTU: Exxua launches as a novel MDD therapy, targeting unmet needs with strong financial discipline - TradingView
Aytu launches EXXUA, first selective 5-HT1A agonist for depression - Investing.com
Aytu BioPharma (AYTU) Launches EXXUA for Treating Major Depressi - GuruFocus
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Di - PharmiWeb.com
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA - ACCESS Newswire
New depression drug EXXUA avoids sexual dysfunction and weight gain - Stock Titan
Will Aytu BioPharma Inc. (AY20) stock outperform global peersREITs Market Trends & Small Investment Big Gains - Bollywood Helpline
Aytu BioPharma Talks Exxua MDD Launch, Differentiation and RxConnect Access at Investor Summit - Defense World
AYTU: Exxua's launch leverages unique differentiation and RxConnect to target major growth in depression treatment - TradingView — Track All Markets
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 - ACCESS Newswire
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City - ACCESS Newswire
How Aytu BioPharma Inc. (AY20) stock reacts to fiscal policiesJuly 2025 Technicals & Stepwise Swing Trade Plans - ulpravda.ru
Buybacks Report: Is Aytu BioPharma Inc. stock dividend yield sustainableForecast Cut & Daily Volume Surge Signals - Улправда
Portfolio Recap: How sustainable is Aytu BioPharma Inc. stock dividend payoutQuarterly Market Summary & AI Enhanced Trading Alerts - Улправда
Why Aytu BioPharma Inc. stock attracts high net worth investorsMarket Risk Report & High Accuracy Trade Alerts - Улправда
Will Aytu BioPharma Inc. stock outperform tech sector in 2025July 2025 Sentiment & High Conviction Investment Ideas - Улправда
Why Aytu BioPharma Inc. stock is favored by top institutionsTreasury Yields & Comprehensive Market Scan Reports - ulpravda.ru
Entry Recap: Why Aytu BioPharma Inc. stock attracts high net worth investorsPortfolio Gains Summary & Weekly Top Stock Performers List - Улправда
Aytu BioPharma (AYTU) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Published on: 2025-12-24 03:59:28 - moha.gov.vn
Can Aytu BioPharma Inc. stock sustain revenue growthJuly 2025 Outlook & Capital Efficiency Focused Strategies - Улправда
Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st
Is Aytu BioPharma Inc. stock attractive for income investors2025 Winners & Losers & Low Risk High Win Rate Picks - Улправда
Aytu BioPharma announces commercial availability of EXXUA tablets - MSN
Will Aytu BioPharma Inc. stock deliver shareholder valueTrade Performance Summary & Low Drawdown Trading Strategies - DonanımHaber
How sustainable is Aytu BioPharma Inc. stock dividend payoutEarnings Growth Summary & Safe Capital Allocation Plans - DonanımHaber
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City - ACCESS Newswire
Depression drug EXXUA takes center stage at New York investor event - Stock Titan
Aytu BioPharma launches depression drug EXXUA in U.S. market - Investing.com India
Aytu BioPharma launches depression drug EXXUA in U.S. market By Investing.com - Investing.com Nigeria
Aytu BioPharma stock rises after commercial launch of depression drug EXXUA - Investing.com Canada
Aytu BioPharma (AYTU) Launches EXXUA for Major Depressive Disorder in U.S. - GuruFocus
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults - Times Argus
Aytu BioPharma (Nasdaq: AYTU) makes EXXUA depression drug commercially available in US - Stock Titan
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome - ACCESS Newswire
AWM Investment Company Inc. Takes $1.35 Million Position in Aytu BioPharma Inc. $AYTU - Defense World
Aytu BioPharma (NASDAQ:AYTU) Given New $13.00 Price Target at Ascendiant Capital Markets - Defense World
1.13%
0.50%
자본화:
|
볼륨(24시간):